MenACWY-PS

also known as ACWYVax · MenACWY-CRM · MPSV4

Developed for: bacterial infectious disease with sepsis · meningitis · meningococcal infection · meningococcemia
Investigated by: Novartis · Novartis Vaccines · University of Oxford

today NCT01593514 · Ph 4 NCT00262002 · Ph 2

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT00262002	Sep 2004 → Jul 2005	meningococcemia	Novartis Vaccines	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT01593514	Dec 2012 → Apr 2013	bacterial infectious disease with sepsis, meningitis, meningococcal infection	University of Oxford	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT00329849 Comparator	May 2006 → Mar 2007	meningococcal infection	Novartis Vaccines	Completed	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	MenACWY PS	“MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent).” NCT00329849 ↗ 2 NCT00262002 ↗ NCT01593514 ↗
Known as	ACWYVax	“The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.” NCT01593514 ↗
Known as	MenACWY-CRM	“MenACWY PS (MenACWY-CRM, polysaccharide vaccine)” NCT00262002 ↗
Known as	MPSV4	“619 healthy children (2-10 years of age) received one dose of an investigational quadrivalent meningococcal CRM(197)-conjugated vaccine (MenACWY-CRM) or a licensed quadrivalent...” PMID 19895922 ↗ Nov 2009
Modality	Vaccine	“MenACWY polysaccharide vaccine” NCT00262002 ↗
Route	Subcutaneous	“One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection” NCT00329849 ↗